Posted 2/27/2024, 6:01:42 PM
Viking Therapeutics Weight-Loss Drug Shows Promise, Outperforms Leading Medicines in Mid-Stage Trial
- Viking Therapeutics' experimental weight-loss drug led to 14.7% average weight loss in a mid-stage trial, outperforming leading drugs like Ozempic and Mounjaro
- The drug works by stimulating hormones that regulate blood sugar and suppress appetite, similar to Eli Lilly's tirzepatide
- Viking's stock price has more than tripled this year on the drug's promise, giving it a market value nearing $7 billion
- The drug did cause some mild/moderate side effects like nausea and vomiting in the trial
- Viking is developing both an injectable form as well as a pill version of the drug, to compete with rivals like Eli Lilly and Novo Nordisk